A correlative study was done to determine possible relationships between nonrandom aberrations in chromosomes 1, 6, and 7 occurring in human cutaneous malignant melanoma and the structure of oncogenes as well as specific genes encoding growth factors and growth factor receptors.
Thirty cell lines derived from primary or metastatic melanomas of 28 patients were analyzed by Southern blotting with nicktranslated probes for 28 different genes, some of which map near frequent chromosomal breakpoints observed in melanoma. An alteration in the MYB protooncogene was observed in a cell line derived from a primary melanoma in the vertical growth phase, which correlated with a 6q22 chromosomal abnormality. Another primary melanoma cell line had a cytogenetically undetected tumor-specific deletion within the gene for a-type protein kinase C. Polymorphic alleles for the genes encoding the epidermal growth factor receptor and a-type protein kinase C were also observed.
In the study of pigmented lesions of the skin, one distinguishes a series of sequential steps (1) that may lead ultimately to the development of cutaneous malignant melanoma (CMM). The first lesion, the common acquired melanocyte nevus, arises from a focal proliferation of structurally normal epidermal melanocytes. Dysplastic nevi are melanocytic nevi with architectural and cytologic atypia. They may occur sporadically or in a familial setting (2) . Progression to melanoma can occur in focal areas within dysplastic nevi. Initially manifested as the radial growth phase without competence for metastasis, primary melanoma then enters the vertical growth phase (VGP), which is associated with metastasis.
This complex tumor progression has been studied with diverse immunologic and genetic methodologies. Monoclonal antibody-defined, tumor-associated antigenic markers of several classes are being evaluated structurally and functionally as markers of tumor progression (see ref. 3 for a review).
Cells of pigmented lesions express receptors for several growth factors such as epidermal growth factor (EGF), insulin-like growth factor (IGF), nerve growth factor (NGF), and platelet-derived growth factor (PDGF). Some growth factors, such as PDGF, produced by melanoma cells (3) are possibly involved in the autocrine mechanism of maintenance of the malignant state (3) (4) (5) . Other investigations have been directed toward identifying the genetic locus involved in the etiology of familial melanoma. Approximately 5-10% of melanoma occurs in individuals with a family history of the disease (6) . Genetic studies of melanoma-prone kindreds indicate a highly penetrant, autosomal, dominant mode of inheritance for a dysplastic nevus syndrome/CMM-susceptibility gene with provisional linkage to the Rh locus on the short arm of chromosome 1 (7, 8) . Experimental transformation of mouse NIH 3T3 cells with human melanoma DNA has detected the sporadic activation of the oncogenes HRAS (9, 10), NRAS (10, 11) , and the RAS-related gene MEL (12, 13) . Cytogenetic studies of melanoma cell cultures have revealed nonrandom chromosomal alterations most frequently involving chromosomes 1, 6, and 7 (14-20) . A recent survey of 48 melanocytic lesions from 37 patients has defined a clustering of deletions and translocations in the lpll-p22 and 6ql2-q25 regions and the presence of extra copies of chromosome 7 (20) .
The present investigation was directed toward the study of VGP primary melanoma and metastatic melanoma because of the ability to maintain these cells in culture and because of their extensive cytogenetic characterization (18, 20) . We have examined the structure of 28 specific genes, which in some instances have been mapped near the locations of the nonrandom chromosomal alterations observed in the melanoma cell lines. As many as 30 human melanoma cell lines derived from 28 (0.2%); the RNA was precipitated with ethanol. Poly(A)+ mRNA was obtained by oligo(dT)-cellulose chromatography (23) . The nuclear pellets were treated with NaDodSO4 (0.6%) and proteinase K (50 ug/ml), and the DNA was extracted with phenol/chloroform. To improve digestion with restriction endonucleases, excess melanin pigment was removed from 250-pg aliquots of DNAs by chromatography (Elutip D column, Schleicher & Schuell). DNA was isolated from peripheral blood lymphocytes (PBL) that had been separated from whole blood by the Ficoll-Paque procedure (Pharmacia). Hybridization Analysis. DNAs were treated with panels of 3-11 restriction endonucleases, electrophoresed on 0.8% agarose gels, and transferred to nitrocellulose filters by the method of Southern (24) . Melanoma cell line poly(A)+ mRNAs were denatured and electrophoresed by the method of Lehrach et al. (25) . Nick-translated human cDNA or genomic probes were prepared for the following genes: IGFI (26); IGF2 (27) ; NGFB (28) Abnormalities. Twenty-three melanoma cell lines were evaluated by DNA blot experiments with 4-10 restriction enzymes and a human MYB cDNA probe designated pML-2, which contains a 2.5-kilobase-pair (kbp) insert corresponding to the 3' end of the message.
Although 22 of the cell lines tested showed no evidence of amplification or rearrangement, changes in the MYB protooncogene were detected with 7 of 10 enzymes in the VGP primary melanoma cell line WM983A. This DNA had aberrant 16.0-kbp EcoRI, 3.7-kbp HindIII; 11.0-kbp EcoRV; 10-kbp Sac I; 6.0-kbp Pst I, and 3.8-kbp BstEII restriction fragments (Fig. LA, lanes 3, 7, 11 , and 19 and Fig. 1B , lanes 7 and 10, respectively). Although lymphocyte DNA was not available from patient WM983, these changes probably represent a structural rearrangement rather than a MYB haplotype because, for example, the 16.0-kb EcoRI fragment has not been observed in 100 other individuals. The aberrant 3.7-kbp HindIII and 3.8-kbp BstEII fragments showed increased electrophoretic mobility relative to all other fragments in these lanes; thus, partial digestion cannot explain these altered restriction patterns. mRNA from the WM983 primary melanoma cell line and two cell lines derived from different metastatic lesions of patient WM983 were found to contain the MYB transcript (not shown); further analysis will be required to determine if the altered MYB allele is active. The MYB alteration does correlate with karyotype data (20) , as cell lines derived from WM983 primary and metastatic lesions are trisomic for chromosome 6-one normal chromosome, one with a 6q22 translocation, and one with a 6q25 deletion. The MYB gene has recently been mapped to 6q22 (53) . The variant MYB hybridizing fragments of WM983 were observed to be less intense, relative to other normal MYB fragments, which is consistent with only one of the three copies of chromosome 6 carrying an altered MYB gene. hybridization analysis (not shown). However, when lymphocyte DNAs obtained from patients WM9 and WM278 were analyzed in parallel with WM9 and WM278 melanoma cell line DNA on a Southern blot, it became clear that the EGFR genes in these two lines were polymorphic and not rearranged in a tumor-specific manner. The variant 9.4-kbp HindIII fragment seen in these melanoma lines were also present in the patients' normal DNA (Fig. 2C, lanes 4 and 6) .
A linkage relationship was observed between HindIIl, EcoRV, Bcl I, and Xba I RFLPs for the EGFR gene, as each of four individuals carried all four of these polymorphisms. Thus, two common alleles (Al at a frequency of 0.26 and A2 at a frequency of 0.74) were defined at this locus as shown in Table 1 . Compared to the Al allele in WM9 and WM278, the Al allele of WM28 may be rearranged, since its polymorphic fragment lengths are relatively longer. However, since lymphocytes were not available from patient WM28, it cannot be ruled out that WM28 carries a third allele similar to Al.
Chromosome 17: Homozygous Deletions Within PKC-a
Gene and Haplotypes for PKC-a Locus. The PKC-a gene was examined by Southern blotting with the pHPKC-a7 cDNA probe (35) for possible alterations not detected cytogenetically. Nineteen melanoma cell lines were cleaved with 11 different restriction enzymes and blotted. One of them, WM278, was shown to carry a homozygous deletion of at least one PKC-a exon. The complete absence of single restriction fragments was observed in 9 different digests. For example, WM278 was missing 10.0-kbp Sac I (Fig. 3A, lane 6) , 11.5-kbp BamHI (Fig. 3B, lane 7) , 4.15-kbp EcoRV (Fig. 3C,  lane 7 ), 1.6-kbp Dra I (Fig. 3D, lane 2) , and 6.9-kbp HindIII (Fig. 3E, lane 3) hybridizing fragments. When lymphocyte DNA from WM278 was digested with HindIII, the deletion was not observed (Fig. 3E, lane 4) . WM278 and each of 10 Proc. Natl. Acad. Sci. USA 85 (1988) 1.6 ft " io qa melanoma lines tested expressed three PKC-a mRNAs that were 9.6 kbp, 3.8 kbp, and 3.1 kbp in size (not shown). Since truncated mRNA species were not observed in WM278 and since only a single 1.6-kbp Dra I genomic fragment was observed, the chromosomal deletion involves only a small quantity of coding sequences. A notable feature of the PKC-a gene is its high degree of base substitutions between alleles. Eight of 11 enzymes used showed RFLPs in 7 of 19 samples. Two different alleles were observed at the PKC-a locus (Al at a frequency of 0.37 and A2 at 0.63). The 10.5-kbp BamHI, 1.9-kbp EcoRV, and 9.4-kbp HindIII RFLPs are demonstrated in Fig. 3 B, C, and E; Table 2 summarizes the linkage pattern of the eight RFLPs. In contrast, the PKC-'y and -P3 genes showed no polymorphism nor structural alteration when the melanoma panel was blotted with 3 different enzymes for the y and / probes.
DISCUSSION
Chromosome studies have provided valuable clues for the identification of cellular oncogenes that may be involved in the development of human leukemias and lymphoma (for a review, see ref. 54 ). The present study applies this strategy to a solid tumor, establishing a possible correlation between a 6q22 chromosomal abnormality and an alteration in the MYB cellular oncogene in a primary melanoma cell line. Isolation and analysis of genomic clones for the altered MYB allele will be required to provide direct evidence for a relationship between the variant MYB restriction pattern observed here and the previous cytogenetic data. Although 6q chromosomal deletions and translocations occur with high frequency in human melanoma (17, 18, 20, 55) , these abnormalities are not all at a specific locus. WM983 was the only 1 of 23 cases studied here that had a chromosomal alteration apparently coinciding with the MYB locus.
The possible involvement of MYB in a human melanoma supports the suggestion (56) that MYB can play a role in the development of solid tumors, in addition to its involvement in myeloid neoplasms. The avian cellular oncogene c-myb has been shown to be the progenitor of the viral oncogene v-myb of the avian myeloblastosis virus (57) , which causes acute myeloblastic leukemia in chickens. In the mouse, Myb is activated by viral insertional mutagenesis in myeloid tumors (58) . In humans, MYB has been shown to be amplified and expressed in a cell line derived from a patient with acute myelogenous leukemia (59) and in a colon adenocarcinoma cell line (56) .
Structural changes in the gene for the EGFR, which maps to chromosome 7 pll-p13 (52) , is not likely to play a major role in melanoma. One of 18 melanoma lines exhibited a possible structural alteration using the pE7 cDNA probe, which spans two-thirds of the coding region; and only 3 of 15 lines synthesized detectable transcripts. Therefore, the significance of the frequently observed extra copy of chromosome 7 in melanoma (60) appears to be unrelated to structural change in the gene. The RFLP demonstrated here characterized by the presence of a 9.4-kbp EGFR HindIII fragment may be an explanation for a variant HindIII fragment of the EGFR gene detected with a similar cDNA probe in two other neoplastic systems (61, 62) .
Although melanoma cell lines generally have apparently normal copies of chromosome 17, the PKC-a gene located at 17q22-q24 (36) was investigated because of its role in the transduction of growth signals from external stimuli. One of 24 melanoma lines, WM278, was shown to carry a submicroscopic deletion within the PKC-a gene. The observed deletion in the PKC-a gene was homozygous in nature, since restriction fragments were lost entirely, rather than being diminished in intensity. The PKC-a restriction fragments seen with most enzymes are complex; Sac I and EcoRV digestions most readily revealed a missing fragment.
Normal cells from the same individual did not have the deletion; thus, it is likely a tumor-specific deletion.
The gross structural alterations observed in the MYB and PKC-a genes were not present in a large proportion of melanoma cell lines. This may indicate that in contrast to the results obtained with leukemias (54) , aberrations in one oncogene may not be implicated in the majority of melanomas, or alternatively, Southern blotting with other or with newly developed oncogene probes may reveal a more frequently rearranged or amplified oncogene in melanoma. On the other hand, different methodological approaches will be required to assess other possible mechanisms of transformation, such as dominant point mutation, the overexpression of a structurally normal gene, or gene inactivation.
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